Advertisement
U.S. markets open in 30 minutes
  • S&P Futures

    5,076.00
    -14.00 (-0.28%)
     
  • Dow Futures

    38,922.00
    -94.00 (-0.24%)
     
  • Nasdaq Futures

    17,942.25
    -78.75 (-0.44%)
     
  • Russell 2000 Futures

    2,047.50
    -12.40 (-0.60%)
     
  • Crude Oil

    79.09
    +0.22 (+0.28%)
     
  • Gold

    2,044.40
    +0.30 (+0.01%)
     
  • Silver

    22.68
    -0.08 (-0.34%)
     
  • EUR/USD

    1.0831
    -0.0018 (-0.16%)
     
  • 10-Yr Bond

    4.2760
    -0.0390 (-0.90%)
     
  • Vix

    13.72
    +0.29 (+2.16%)
     
  • GBP/USD

    1.2645
    -0.0042 (-0.33%)
     
  • USD/JPY

    150.7390
    +0.2590 (+0.17%)
     
  • Bitcoin USD

    60,518.67
    +3,434.29 (+6.02%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,625.85
    -57.17 (-0.74%)
     
  • Nikkei 225

    39,208.03
    -31.49 (-0.08%)
     

Mangoceuticals Selects TRYBE Labs as its Nationwide Blood Collection and Testing Services Provider

Mangoceuticals, Inc.
Mangoceuticals, Inc.

TRYBE Labs to provide MangoRx customers with turnkey at-home blood collection services and solutions

Dallas, Texas, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product branded ‘GROW’ and erectile dysfunction (ED) drug branded “Mango,” today announced that it has selected TRYBE Labs to provide its customers with a minimally invasive FDA approved at-home blood collection device and testing services as the Company seeks to further expand its product lines requiring blood tests and results reviewed by physicians.

Using innovative, FDA approved at-home blood collection technology, TRYBE Labs is a CLIA certified and Joint Commission accredited laboratory that provides a direct-to-consumer product which includes an easy-to-use collection kit, full range of testing, and physician-read results for male health and performance evaluation - including hormone, thyroid and vitamin levels.

“As we have been continuously working to bring additional pharmaceutical based products and solutions to market, the requirement for our physicians to review up-to-date blood work and results has become paramount,” said Jacob Cohen, MangoRx’s co-founder and CEO. “TRYBE Labs offers a unique, innovative, convenient, and minimally invasive approach for blood collection and testing along with fast result turnaround times (in as little as 72 hours) for patients across the United States. What makes our partnership that much greater is that TRYBE Labs and MangoRx are completely aligned with our respective approaches in being disruptive in our industries and we are thrilled to work with them and their team on this endeavor.”

TRYBE Labs will also be joining the Company as one of their affiliate marketing partners to further create awareness and drive sales of MangoRx’s men’s health and wellness related products through its own direct-to-consumer marketing efforts.

“TRYBE Labs was built by men, for men,” said Lewis Scalione, Founding Partner, TRYBE Labs. “We know many men are hesitant to seek medical care and that they may struggle with the perceived stigma that comes with low energy or suboptimal performance - at the gym or in the intimate moments of their lives. By putting the power of information and cutting-edge technology directly into their hands, we are making healthcare more accessible to all who need it.”

About MangoRx
MangoRx is focused on developing a variety of men's health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men's wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED) and hair growth. Interested consumers can use MangoRx’s telemedicine platform for a smooth medical prescription that is exclusively compounded for each individual. Orders will then be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com or on social media @Mango.Rx.

About TRYBE Labs
TRYBE Labs is the only FDA-approved, at-home collection and testing service on the market today that is designed specifically for men. With an interactive online portal for monitoring, scoring and tracking of results, TRYBE Labs is delivering the future of men’s health today. Visit trybelabs.us.

Cautionary Note Regarding Forward-Looking Statements

Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 ("forward-looking statements"). These forward-looking statements represent the Company's current expectations or beliefs concerning future events and can generally be identified using statements that include words such as "estimate," "expects," "project," "believe," "anticipate," "intend," "plan," "foresee," "forecast," "likely," "will," "target" or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company's control which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, including, but not limited to; our ability to obtain additional funding and generate revenues to support our operations; risks associated with our ED product which have not been, and will not be, approved by the U.S. Food and Drug Administration ("FDA") and have not had the benefit of the FDA's clinical trial protocol which seeks to prevent the possibility of serious patient injury and death; risks that the FDA may determine that the compounding of our planned products does not fall within the exemption from the Federal Food, Drug, and Cosmetic Act ("FFDCA Act") provided by Section 503A; risks associated with related party relationships and agreements; the effect of data security breaches, malicious code and/or hackers; competition and our ability to create a well-known brand name; changes in consumer tastes and preferences; material changes and/or terminations of our relationships with key parties; significant product returns from customers, product liability, recalls and litigation associated with tainted products or products found to cause health issues; our ability to innovate, expand our offerings and compete against competitors which may have greater resources; our significant reliance on related party transactions; the projected size of the potential market for our technologies and products; risks related to the fact that our Chairman and Chief Executive Officer, Jacob D. Cohen and President, Jonathan Arango, combined have majority voting control over the Company; risks related to the significant number of shares in the public float, our share volume, the effect of sales of a significant number of shares in the marketplace, and the fact that the majority of our shareholders paid less for their shares than the public offering price of our common stock in our recent initial public offering; the fact that we have a significant number of outstanding warrants to purchase shares of common stock at $1.00 per share, the resale of which underlying shares have been registered under the Securities Act of 1933, as amended; our ability to build and maintain our brand; cybersecurity, information systems and fraud risks and problems with our websites; changes in, and our compliance with, rules and regulations affecting our operations, sales, marketing and/or our products; shipping, production or manufacturing delays; regulations we are required to comply with in connection with our operations, manufacturing, labeling and shipping; our dependency on third-parties to prescribe and compound our ED product; our ability to establish or maintain relations and/or relationships with third-parties; potential safety risks associated with our Mango ED product, including the use of ingredients, combination of such ingredients and the dosages thereof; the effects of high inflation, increasing interest rates and economic downturns, including potential recessions, as well as macroeconomic, geopolitical, health and industry trends, pandemics, acts of war (including the ongoing Ukraine/Russian conflict) and other large-scale crises; our ability to protect intellectual property rights; our ability to attract and retain key personnel to manage our business effectively; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; overhang which may reduce the value of our common stock; volatility in the trading price of our common stock; and general consumer sentiment and economic conditions that may affect levels of discretionary customer purchases of the Company's products, including potential recessions and global economic slowdowns. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements we make in this release are reasonable, we provide no assurance that these plans, intentions or expectations will be achieved. Consequently, you should not consider any such list to be a complete set of all potential risks and uncertainties.

More information on potential factors that could affect the Company's financial results is included from time to time in the "Cautionary Note Regarding Forward-Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's filings with the SEC, including the Company’s Quarterly Report on Form 10-Q for the Quarter ended September 30, 2023. These filings are available at www.sec.gov and at our website at https://www.mangoceuticals.com/sec-filings. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Follow Mangoceuticals and MangoRx on social media:
https://www.instagram.com/mango.rx
https://twitter.com/Mangoceuticals
https://www.facebook.com/MangoRxOfficial

FOR PUBLIC RELATIONS
Lucky Break Public Relations
Sahra Simpson
Sahra@luckybreakpr.com
(323) 602-0091 ext. 704

FOR INVESTOR RELATIONS
Mangoceuticals Investor Relations
Email: investors@mangorx.com

MEDIA CONTACT
PHOENIX MGMT Marketing & Consulting
info@phoenix-mediamarketing.com

SOURCE: Mangoceuticals Inc.


Advertisement